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Effective bidirectional signalling between axons and Schwann cells is essential for both the development and maintenance of
peripheral nerve function. We have established conditions by which human induced pluripotent stem cell-derived sensory neurons
can be cultured with rat Schwann cells, and have produced for the ﬁrst time long-term and stable myelinating co-cultures with
human neurons. These cultures contain the specialized domains formed by axonal interaction with myelinating Schwann cells, such
as clustered voltage-gated sodium channels at the node of Ranvier and Shaker-type potassium channel (Kv1.2) at the juxtapar-
anode. Expression of type III neuregulin-1 (TIIINRG1) in induced pluripotent stem cell-derived sensory neurons strongly enhances
myelination, while conversely pharmacological blockade of the NRG1-ErbB pathway prevents myelination, providing direct evi-
dence for the ability of this pathway to promote the myelination of human sensory axons. The b-secretase, BACE1 is a protease
needed to generate active NRG1 from the full-length form. Due to the fact that it also cleaves amyloid precursor protein, BACE1 is
a therapeutic target in Alzheimer’s disease, however, consistent with its role in NRG1 processing we ﬁnd that BACE1 inhibition
signiﬁcantly impairs myelination in our co-culture system. In order to exploit co-cultures to address other clinically relevant
problems, they were exposed to anti-disialosyl ganglioside antibodies, including those derived from a patient with a sensory
predominant, inﬂammatory neuropathy with mixed axonal and demyelinating electrophysiology. The co-cultures reveal that
both mouse and human disialosyl antibodies target the nodal axolemma, induce acute axonal degeneration in the presence of
complement, and impair myelination. The human, neuropathy-associated IgM antibody is also shown to induce complement-
independent demyelination. Myelinating co-cultures using human induced pluripotent stem cell-derived sensory neurons thus
provide insights into the cellular and molecular specialization of axoglial signalling, how pharmacological agents may promote
or impede such signalling and the pathogenic effects of ganglioside antibodies.
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Introduction
There is a close anatomical and metabolic relationship be-
tween axons and Schwann cells such that the health of each
cell type is intimately dependent on the other. Axoglial
signalling is critical for myelination and can be disturbed
in pathological states (Taveggia et al., 2010). The use of
primary rodent cells (dorsal root ganglion neurons and
Schwann cells) in the generation of myelinating co-cultures
led to great progress in understanding the interactions be-
tween these two cell types, showing for instance that the
axolemma contains a signal that could promote Schwann
cell proliferation (Wood and Bunge, 1975; Salzer et al.,
1980). This was subsequently identiﬁed as neuregulin-1
(Morrissey et al., 1995). The type III neuregulin-1 isoform
(TIIINRG1) is expressed on the axolemma of large diam-
eter axons and signals in a juxtacrine manner (via ErbB 2/3
heterodimers expressed by Schwann cells) to promote axon
ensheathment and myelination (Garratt et al., 2000;
Michailov et al., 2004; Taveggia et al., 2005). Co-cultures
recapitulate many of the sequential features of myelination
observed in vivo, including Schwann cell alignment to
axons, ensheathment of the axon by the Schwann cell pro-
cess and ﬁnally membrane wrapping and compaction. The
intercellular interactions between axons and Schwann cells
during myelination result in the formation of axonal do-
mains with specialised molecular constituents (Rasband and
Peles, 2016). For instance, voltage gated sodium channels
(VGSCs) are clustered at the node of Ranvier, ﬂanked by
the paranodes where tight adherence of the Schwann cell
paranodal loops to the axon act as a diffusion barrier,
separating VGSCs from potassium channels in the
juxtaparanode.
Human induced pluripotent stem cells (iPSCs) are in-
creasingly used in model systems of neurological disorders
(Sandoe and Eggan, 2013; Corti et al., 2015). They facili-
tate the study of human proteins in their normal cellular
context, and, through the reprogramming of patient-
derived samples, allow the impact of mutations to be inves-
tigated within a relevant polygenetic background. They can
be used for pharmacological studies, toxicity screening, to
investigate immunopathological mechanisms, and to assess
the reactivity of cells/antisera towards human antigens.
Culture protocols have advanced such that instead of
focussing on single cell types it is possible to investigate
intercellular interactions and more complex tissues. This
approach has been used to investigate central myelin
(Czepiel et al., 2015) but has not previously been used to
study axoglial signalling and myelination in the peripheral
nervous system. We report here that sensory neurons dif-
ferentiated from human iPSCs can be effectively and reli-
ably myelinated by rat Schwann cells. These myelinating
co-cultures display the expected features of axonal and
Schwann cell specialization.
In inﬂammatory neuropathies such as Guillain Barre´ syn-
drome (GBS) and chronic inﬂammatory demyelinating
polyneuropathy (CIDP), axoglial proteins and glycolipids
are important targets for the underlying autoimmune pro-
cess (Willison and Yuki, 2002; Devaux et al., 2012). In a
subset of patients, neuropathy-associated antibodies specif-
ically target neo-epitopes formed by cis and trans inter-
actions between different axonal and glial molecules
(Querol et al., 2013; Rinaldi et al., 2013). Recreating
these interactions in solid phase systems has proved difﬁ-
cult. Problems with existing assays are further evidenced by
the inconsistent relationship between antibody binding
in vitro and pathogenic effects in vivo (Greenshields
et al., 2009). Anti-disialosyl ganglioside antibodies, which
bind to alpha2-8 linked disialic acid residues (as found in
GD3, GD1b, GT1b and GQ1b), are associated with pre-
dominantly sensory and/or ataxic neuropathies. Disialosyl
antibodies of the IgM class are a deﬁning feature of
CANOMAD (chronic ataxic neuropathy with ophthalmo-
plegia M-protein, cold agglutinins and anti-disialosyl anti-
bodies). This neuropathy shows both axonal and
demyelinating features on electrophysiology (Willison
et al., 2001). Disialosyl antibodies of the IgG class have
been found in acute sensory neuropathies, some with un-
equivocal electrophysiological evidence of demyelination in
the form of temporal dispersion (Wicklein et al., 1997;
Miyazaki et al., 2001). However, immunization of rabbits
with GD1b that raised IgM and IgG antibodies induced a
sensory neuropathy characterized pathologically by down-
regulation of the neurotrophin-3 receptor, trkC, and by the
degeneration of sensory axons and DRG neurons
(Kusunoki et al., 1996; Hitoshi et al., 1999). In this
report, we exploit the myelinating co-cultures to show
that both mouse IgG and human, neuropathy-associated
IgM type anti-disialosyl antibodies bind to human iPSC-
derived sensory axons at the nodal axolemma and, in
addition to inducing acute complement mediated axonal
degeneration, have deleterious, complement-independent
effects on myelination.
Materials and methods
Induced pluripotent stem cell
generation
NHDF1 (from 44-year-old female) was reprogrammed with
Yamanaka retroviruses SOX2, KLF4, OCT3/4, c-MYC and
NANOG (Takahashi et al., 2006), and has previously been
described (Hartﬁeld et al., 2014). AH017-7 (from 67-year-
old female) has also previously been described (Handel et al.,
2016) and was reprogrammed using the SeVdp(KOSM)302L
Sendai virus system, containing genes for KLF4, OCT3/4,
SOX2 and c-MYC, expressed from a single transcript and
packaged into a single Sendai virus to ensure consistency of
gene dosage ratio (Nishimura et al., 2011, 2013). AD2-1 (from
51-year-old male) was reprogrammed using the CytoTuneTM-
iPS Reprogramming Kit (ThermoFisher) and will be described
in an upcoming publication (Buskin et al., in press). The ﬁbro-
blasts to generate AD2-1 were obtained from a commercial
Myelinating co-cultures BRAIN 2017: 140; 898–913 | 899
source (Lonza, CC-2511). Further details are supplied in the
Supplementary material.
The iPSC line AD2-1 were obtained through the IMI/EU
sponsored StemBANCC consortium via the Human
Biomaterials Resource Centre, University of Birmingham, UK
(http://www.birmingham.ac.uk/facilities/hbrc).
iPSC lines were also subject to strict quality control
checks before the initiation of differentiation. Quality control
details for AD2-1 are explained in van de Bunt et al. (2016).
Brieﬂy, this included tests for Sendai virus clearance, FACS for
pluripotency markers, genomic integrity checks and embryoid
body tri-lineage differentiation experiments. Cells are also con-
ﬁrmed as negative for Mycoplasma before cryopreservation.
Induced pluripotent stem cell
maintenance and differentiation
iPSCs were defrosted, plated onto Matrigel

coated plastic and
maintained in mTeSR1 medium, which was exchanged daily.
iPSCs were passaged when 90% conﬂuent onto Matrigel

coated plasticware using TrypLE express (ThermoFisher). Rho-
associated, coiled-coil containing protein kinase (ROCK) inhibi-
tor (ScienCell) (10mM) was included in the medium for 24h
after each passage. Prior to the start of differentiation, iPSCs
were plated onto Matrigel

coated 6-well plates. Twenty-four
hours later, the medium was exchanged from mTeSR1 to mouse
embryonic ﬁbroblast conditioned medium (ScienCell) supple-
mented with 10ng/ml human recombinant FGF2. Cells were
allowed to expand in MEF-conditioned medium until 50%
conﬂuent, at which time differentiation was started according
to Chambers et al. (2012) (detailed differentiation protocol in
Supplementary material). This differentiation resulted in a pure
neuronal culture with extensive aborized neurites by 2–3 weeks
after the end of the small inhibitor stage.
Schwann cell harvesting and culture
All work using animals conformed to UK Home Ofﬁce legisla-
tion (Scientiﬁc Procedures Act 1986). Schwann cells were har-
vested from the sciatic nerve and brachial plexus of postnatal
Day 3 or 4 rats. Rat Schwann cells are used as well established
culture protocols exist and they can be successfully expanded
several times in vitro in order to create cryopreserved stocks.
Nerves were enzymatically digested with a collagenase (Sigma,
3mg/ml) and dispase II protease (Sigma, 2.5mg/ml) incubation
for 1h at 37C. Nerves were gently triturated using a P1000
pipette tip and plated onto PDL/laminin coated plastic in
Schwann cell expansion medium [DMEM/F12 (ThermoFisher),
10% foetal bovine serum (ThermoFisher), 200ng/ml NRG1-b1
EGF domain (R&D Systems), 10ng/ml NGF (recombinant-
murine, Peprotech), 4mg/ml forskolin (Sigma)]. Cells were seri-
ally treated with 5–10mM araC to eliminate ﬁbroblasts. After
approximately four passages, each time doubling the growing
area, cells were frozen in a Mr Frosty freezing container
(ThermoFisher), and stored in liquid nitrogen.
Establishing the myelinating
co-cultures
To establish the co-cultures, a frozen vial of Schwann cells was
thawed in warm water, centrifuged in phosphate-buffered saline
(PBS) and resuspended in Schwann cell basal medium [DMEM/
F12 (ThermoFisher), 5mg/ml insulin (Sigma), 100mg/ml transfer-
rin (Millipore), 25ng/ml NGF (recombinant-human, Peprotech),
25ng/ml Selenium (Sigma), 25ng/ml thyroxine (Sigma), 30ng/ml
progesterone (Sigma), 25ng/ml triiodothyronine (Sigma), 8mg/ml
putrescine (Sigma)]. The medium on the neuronal cultures
was changed from N2 to Schwann cell basal medium.
Schwann cells (25000) in a 25ml droplet were slowly pipetted
onto a single coverslip containing the iPSC-derived neurons,
with care taken not to touch the coverslip with the pipette tip.
The Schwann cell droplet was evenly distributed over the cover-
slip. Cultures were carefully put back into the incubator to
allow Schwann cell adherence. The culture medium was changed
2 days later. At this stage abundant Schwann cells can be
observed adhered to the coverslip. An additional Schwann
cell basal medium change was performed 4 days after adding
the Schwann cells. During the 1-week period when the human
iPSC-derived neurons are cultured in Schwann cell basal medium
we observe no detrimental effects to the neurons, such as neurite
blebbing. Myelination was induced 1 week after Schwann
cell addition, by exposing the cells to myelination medium [N2
medium, 1:300 phenol-free Matrigel

(Scientiﬁc Laboratory
Supplies), 5% charcoal-stripped FBS (ThermoFisher), 25ng/ml
NGF (recombinant-human, Peprotech), 50mg/ml ascorbic acid
(Sigma)]. Medium changes were performed twice weekly from
then on.
When optimizing the culture conditions required to establish
myelinating co-cultures, we observed that the Schwann cells
proliferate and align to the human axons during the week
after seeding them onto the neurons; this is aided by keeping
the co-cultures in Schwann cell basal medium. However, we
noticed that simply supplementing the Schwann cell basal
medium with ascorbic acid (as usually performed when cultur-
ing primary DRG neurons and Schwann cells together) re-
sulted in only the occasional formation of myelin internodes.
Furthermore, after 3–4 weeks these cultures gradually began
to show signs of a decline in neuronal health, such as neurite
blebbing. We therefore adapted commonly used protocols
when generating myelinating co-cultures using primary
rodent cells, by using myelination medium that is largely for-
mulated to encourage the growth and wellbeing of the neu-
rons. We found that using the neuronal medium, with the
addition of Matrigel

and ascorbic acid greatly improved
both neuronal health, alignment by Schwann cells and the
levels of myelination. This adaptation in medium allowed us
to establish healthy and stable myelinating co-cultures between
rat Schwann cells and human iPSC-derived neurons that could
be kept for many months without signs of a gradual decline in
cellular health.
AAV transduction
For AAV8-Nrg1 type-III production, rat NRG1 type-III was
subcloned into an AAV vector. Type-III-b1a constructs were a
gift from Dr Douglas L. Falls (Emory University, Atlanta,
USA) (Wang et al., 2001). A 2.3kb EcoNI/PsiI insert was
cloned from the original PcDNA3.1 vector into the EcoR1
site of a pAAV-CAG vector. The AAV viral packaging, CsCl
puriﬁcation and viral genome titration were performed by
Vector Biolabs.
Neuronal cultures were transduced 3 weeks after plating
neurons onto coverslips. After infection, neurons were left
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for 7 days before the addition of Schwann cells. The stock
virus was diluted in N2 medium to the correct multiplicity
of infection (MOI) based on 25 000 cells per coverslip. N2
medium containing the AAV was then transferred to the neur-
onal cultures, and left for 3 days. An N2 plus neurotrophins
medium change was performed on Days 3 and 5 after infec-
tion, and Schwann cells were added on Day 7. Co-cultures
were then kept in Schwann cell basal medium for 7 days,
before inducing myelination (as described above).
Immunocytochemistry and confocal
imaging
For immunocytochemistry, coverslips were transferred to PBS,
and ﬁxed in 1% paraformaldehyde for 20min. Cells were
washed three times in PBS and then permeabilized in ice
cold methanol for 20min. Following three PBS washes, cells
were blocked [5% donkey serum, 0.3% milk powder, 1%
bovine serum albumin (BSA), 0.1% sodium azide, 1% dime-
thyl sulphoxide (DMSO)], washed in PBS, and incubated with
the primary antibody overnight at 4C. Cells were then
washed with PBS, and incubated with the secondary antibody
for 2 h at room temperature. The secondary antibody was
washed off with PBS, and the coverslips were mounted onto
Superfrost Plus microscope slides (Thermo Scientiﬁc) in
Vectashield mounting medium (Vector Laboratories). Primary
antibodies used and their dilations are indicated in the
Supplementary material. Secondary antibodies used were
Alexa Fluor 568, 546, 488, 405 or Paciﬁc Blue.
Myelination was quantiﬁed via confocal microscopy using
systematic random sampling to ensure objective sampling
across the coverslip. See Supplementary material for additional
detail.
NF200-positive surface area was taken as a measurement of
axon area, while myelin basic protein (MBP) positive surface
was used as a measurement of myelin area. Since measuring
MBP area was a novel approach to quantify myelination, we
cross-validated our results by comparing them to the most
commonly used method (myelin internode count). We counted
the number of internodes and quantiﬁed the myelin area in 18
separate myelinated co-culture coverslips within a single neur-
onal differentiation and found both set of results were highly
correlated (Pearson’s R; r = 0.962, n = 18, P5 0.001;
Supplementary Fig. 1). Hence, measurement of MBP surface
area was used to quantify myelination, as it provided the more
time efﬁcient method. When comparing between conditions,
the proportion of the total axonal area covered by myelin
(MBP area/NF200 area) was calculated, and expressed as a
fold change from control. To acquire cell numbers, DAPI posi-
tive nuclei were quantiﬁed using ‘Particle Analyser’ provided
by ImageJ software.
Pharmacological blockade of NRG1-
ErbB signalling
Pharmacological inhibition of ErbB/NRG1 signalling was per-
formed using the selective and irreversible ErbB inhibitor,
PD168393 (7 and 70 nM, reconstituted in DMSO,
Calbiochem), and the b-secretase inhibitor IV (50 and
500nM, reconstituted in DMSO, Calbiochem) that binds to
BACE1 active site, blocking its proteolytic activity.
Compounds were included in the cell culture myelination
medium at all medium changes, at the stated concentrations.
Control conditions included the vehicle of the compound
(DMSO) at the same concentration. Cells were cultured for
4 weeks with twice weekly medium changes before ﬁxation
and image processing.
Transmission electron microscopy
Cells adhered to coverslips were ﬁxed, dehydrated, inﬁltrated
with epoxy resin and embedded into Agar100 resin. The
coverslip was snapped off, leaving the cells embedded as a
monolayer on the surface of the block. Ultrathin sections
were cut, mounted, post-stained and imaged. Detailed instruc-
tions can be found in Supplementary material.
Anti-disialosyl antibody treatment
The mouse monoclonal IgG antibodies MOG12 and EG4 were
produced and puriﬁed from hybridomas cloned by limiting
dilution after GT1b or GQ1b ganglioside immunization (re-
spectively) of GD3-synthase deﬁcient mice, as previously
described (Boffey et al., 2005). The human monoclonal IgM
antibody HA1 was cloned after EBV transformation of periph-
eral blood mononuclear cells taken from a patient with
CANOMAD, as previously described (Willison et al., 1996).
All of these anti-ganglioside antibodies cross-react with struc-
turally similar gangliosides containing disialosyl groups,
including GD1b, GD3, GT1a, GT1b and GQ1b. Herein,
they are referred to as ‘anti-disialosyl’ antibodies to reﬂect
this reactivity. Normal mouse IgG was obtained from
Abcam. To identify topographical binding patterns, the culture
media of mature co-cultures were supplemented with anti-dis-
ialosyl antibodies at 100mg/ml and incubated at 37C for 16 h.
To assess the effects of complement, culture media were sub-
sequently supplemented with 20% normal human serum and
re-incubated at 37C for 2 h. Immunocytochemistry and con-
focal imaging were then performed, as described above. To
assess their effects on myelination, anti-disialosyl antibodies
were added to every change of medium for the ﬁrst 4 weeks
after myelination was induced, at both low (10 mg/ml) and
high (EG4 40 mg/ml, MOG12 and HA1 50 mg/ml) concentra-
tions, without the addition of normal human serum.
Experiments were repeated with three different iPSC differen-
tiations. Controls were treated with myelination medium only,
or with identical concentrations of normal mouse IgG. After 4
weeks, cells were ﬁxed, the entire axonal ﬁeld was imaged, and
the proportion of the NF200 positive axonal area covered by
MBP positive myelin was calculated as before.
To assess effects on established myelin, co-cultures aged 9 to
12 months from three different iPSC lines were used. At base-
line, myelination medium was supplemented with ﬂuoromyelin
red (Fisher Scientiﬁc) at a 1:300 dilution, and incubated at
37C for 16 h. The extent of baseline myelination was re-
corded by imaging live cells over a 2688 mm  2688 mm
centred grid at 10  objective magniﬁcation. Images took less
than 3min to acquire per coverslip. Automated stage move-
ment with deﬁned coordinates were used to allow serial ima-
ging of the same areas. After baseline imaging, myelination
medium was replaced. From this point on, the human IgM
HA1 was added to each change of medium for the next
4 weeks. Control coverslips were treated with standard
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myelination medium only. After 4 weeks, cultures were ﬁxed
and axon and myelin coverage was assessed by immunoﬂuor-
escence with NF200 and MBP primary antibodies, as before.
To identify areas of demyelination, the ﬂuoromyelin image
from baseline was overlain with the MBP channel image at
4 weeks, in which the background had been made transparent.
The area of ﬂuoromyelin signal (at baseline) without a corres-
ponding MBP signal (after 4 weeks) was calculated using
ImageJ, and expressed as a proportion of the total ﬂuoromye-
lin area at baseline. Areas of ongoing demyelination, identiﬁed
by ‘fragmented’ MBP staining replacing linear ﬂuoromyelin
staining, were also imaged at higher power (63 objective)
to assess the integrity of demyelinated axons.
Statistics
Statistical analysis was performed using IBM SPSS Statistics for
Mac (Version 22). Student’s t-test was used for comparison of
two groups, one-way ANOVA using Tukey post hoc correc-
tion was used for more than two groups. Correlation was
analysed using Pearson’s R. Results are reported as
mean  SEM. Asterisks indicate the level of signiﬁcance
(P5 0.001, P50.01, P50.05).
Results
Alignment and myelination of human
induced pluripotent stem cell-derived
sensory neurons by rat Schwann cells
We found that the key step in promoting myelination in co-
cultures of human iPSC-derived sensory neurons and rat
Schwann cells was to use a neuronal base medium with
Matrigel

in the myelinating medium stage rather than a
Schwann cell basal medium. This gave rise to long-lasting
stable co-cultures in which neuronal health was maintained
and a much greater efﬁciency of myelination. To investigate
how human iPSC-derived sensory neurons interacted with
primary rat Schwann cells, co-cultures were investigated for
canonical markers of the Schwann cell-axon relationship.
Initially, sensory neurons were ﬁrst differentiated using the
previously published protocol (Chambers et al., 2012).
These neurons grew extensive arborized neurites, and
490% of cells were positive for the sensory neuron tran-
scription factor BRN3A (Fig. 1A). After allowing the neu-
rons to mature and grow widespread neurite processes for
2 weeks, rat Schwann cells were added in suspension, these
adhered to the coverslip and were allowed to migrate and
come in contact with axons for 1 week before myelination
was induced (schematic and timeline of co-culture shown in
Fig. 1B). In that time, alignment and Schwann cell-axon
interaction was observed by the expression of N-cadherin
at the cell-to-cell interface (Fig. 1C, arrowheads), as has
been described in primary co-cultures of DRGs and
Schwann cells (Wanner and Wood, 2002). Staining the
Schwann cell cytoplasm with an antibody directed against
S100 revealed the typical bipolar Schwann cell morphology
that was closely aligned to the NF200 positive axon of the
sensory neuron (Fig. 1D). As the tightly associated rat
Schwann cell begins to form the axon/Schwann cell com-
plex before the onset of myelination, increased levels of
extracellular matrix are observed (collagen IV), indicating
the beginning of basal lamina formation (Fig. 1E). The ﬁrst
MBP positive internodes were observed after 2 weeks of
ascorbic acid supplementation, and gradually increased
over time in culture (Fig. 3). After 6 weeks of myelination,
abundant MBP positive internodes are detected throughout
the culture (Fig. 1F). On a transcriptional level, Schwann
cells followed a typical transition into a mature myelinating
state; basal expression of the transcription factor SOX10
was present in all Schwann cells, but not in neuronal nuclei
(arrowheads, Fig. 1H). Upon induction of myelination, rat
Schwann cells associated with MBP positive internodes
showed strong upregulation of KROX20 (Fig. 1I), while
the expression of c-JUN was not detected in these cells
(Fig. 1G, arrowhead depicts a Schwann cell nucleus asso-
ciated with an MBP positive internode that is negative for
c-JUN), consistent with the cross antagonistic relationship
between these transcription factors (Parkinson et al., 2008).
Taken together, these myelinating co-cultures of rat
Schwann cell and human iPSC-derived sensory neurons ex-
press the canonical markers of an axoglial relationship, and
we demonstrate for the ﬁrst time that there is successful
cross-species signalling in order to initiate alignment,
basal lamina formation and myelination.
Node of Ranvier formation and
maturation of the myelin sheath
We detected characteristic nodal structures in our 6-week
myelinated co-cultures using antibodies directed against
proteins localized to the specialized axonal domains that
form at the node of Ranvier, the paranode and the juxta-
paranode. Caspr (contactin-associated protein)-positive
paranodes encompassed dense clusters of voltage gated
sodium channels at the nodes (using an antibody that rec-
ognizes a sequence from the intracellular III-IV loop present
in all vertebrate Nav channels) (Fig. 2A and B). The shaker
type voltage gated potassium channel (Kv1.2) was localized
in adjacent juxtaparanodes (Fig. 2A). Nodes of Ranvier
were abundantly detected throughout the culture at this
time point, with the occasional heminode also present
(Fig. 2C).
Myelin sheath ultrastructure was viewed with electron
microscopy at 6 and 14 weeks post-myelination. At this
resolution individual myelin wraps and the basal lamina
around the Schwann cell/axon complex could be observed
(arrowheads, Fig. 2D). At the earlier time point, several
axons were observed where the myelin wraps were not
compacted (arrow Fig. 2D). Increasing numbers of myelin
wraps and a more compacted myelin structure were
observed at the later time point indicating the typical mat-
uration of the myelin sheath (Fig. 2D).
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Myelination increases over time
To investigate the time course of myelination in the co-cul-
tures, myelin coverage was quantiﬁed at 2, 3, 4, 6 and 14
weeks post-induction. Representative images used for the
quantiﬁcation are illustrated in Fig. 3(A–E). As expected,
an overall signiﬁcant increase in the quantity of myelin was
observed over time [Fig. 3G, ANOVA, F(4,17) = 9.616,
P50.001], however the axonal coverage did not signiﬁ-
cantly change over time [Fig. 3F, ANOVA, F(4,17) = 2.735,
P40.05], indicating that the increase in myelin is not
simply due to greater axonal outgrowth. Furthermore,
these cultures are extremely stable, and have been main-
tained for over 9 months with no loss of myelin or
neuron integrity (Supplementary Fig. 2).
To assess the levels of myelination across different iPSC
lines, we differentiated three separate control lines to sen-
sory neurons and co-cultured them with rat Schwann cells
as described in the methods. All three iPSC-derived
neuronal cultures were successfully myelinated and the
levels of myelination were very similar between cell lines
(Supplementary Fig. 3) demonstrating the reproducibility of
this co-culture system.
Overexpression of NRG1 type III
influences levels of myelination
TIIINRG1 expression at the axonal surface has been estab-
lished as one of the key regulators of myelination. To in-
vestigate the role of TIIINRG1 in the present co-culture
system, human iPSC-derived neurons were transduced
with an AAV containing a TIIINRG1 construct at a
range of MOIs (1  104 to 1  106, Fig. 4B–D). Viral
transduction was well tolerated by iPSC-derived neurons,
as no difference in axon area (Fig. 4E) [ANOVA, F(3,17)
= 1.103, P4 0.05] or visible signs of cellular stress were
observed across different conditions (Fig. 4A–D). Neuronal
Figure 1 Rat Schwann cells align and myelinate human iPSC-derived sensory neurons. (A) Sensory neurons can be differentiated
from iPSCs, identified through BRN3A positive nuclei, and these grow extensive NF200 immunoreactive neurite processes. (B) Schematic
showing the establishment of the myelinating co-cultures. (C) As rat Schwann cells migrate and come into contact with human axons, N-cadherin
expression is upregulated at the interface between the axon and Schwann cell (arrowheads). (D) The S100 immunoreactive Schwann cell tightly
aligns to the human axon. (E) Collagen expression is upregulated as the basal lamina forms around the Schwann cell/axon complex. (F) MBP
positive internodes are abundant throughout the co-cultures after 6 weeks of myelination. (G) Myelinating Schwann cells do not express c-Jun
(arrowhead highlights a c-Jun negative nucleus) in contrast to non-myelinating Schwann cells. (H) Rat Schwann cells are SOX10 positive, whereas
the neurons (NF200 positive, arrowheads) do not express SOX10. (I) Myelinating Schwann cells express KROX20.
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overexpression of TIIINRG1 type caused a signiﬁcant in-
crease in the formation of myelin at 4 weeks (Fig. 4F)
[ANOVA, F(3,17) = 47.87, P5 0.001], with 4.8-fold and
13-fold increase with 1  105 and 1  106 MOI, respect-
ively. Full-length (FL) and the cleaved-terminal fragment
(CTF, formed following proteolytic processing) of
TIIINRG1 protein expression was increased in the
1  105 and 1  106 MOI condition compared to untrans-
duced basal expression (Fig. 4G), which signiﬁcantly
increased the levels of myelination in both conditions
(Fig. 4F). Interestingly, viral transduction with 1  104
MOI concentration led to some increase in the protein
levels of both the full-length and cleaved-terminal fragment
(Fig. 4G), without inﬂuencing the levels of myelination
(Fig. 4F) suggesting a possible threshold effect, furthermore
assessing total NRG1 levels is only a partial reﬂection of
TIIINRG1 protein at the axoglial interface.
Pharmacological blockade of NRG1-
ErbB signalling leads to impaired
myelination
Neuregulins belong to the family of EGF domain-contain-
ing proteins and interact with and activate receptor tyrosine
kinases of the ErbB family expressed by Schwann cells
(ErbB2 and ErbB3). The selective and irreversible ErbB in-
hibitor PD168393 was used to block ErbB receptors and
prevent TIIINRG1 signal transduction. As expected, a dose-
dependent reduction in myelination was detected in the
presence of PD168393 inhibitor (Fig. 5B, C and F)
[ANOVA, F(2,14) = 14.87, P5 0.001]. TIIINRG1 requires
proteolytic cleavage by proteases to expose its active EGF-
domain (Hu et al., 2006; Willem et al., 2006; Fleck et al.,
2016). The cell-permeable isophthalamide that binds to
BACE-1 active site was used to block its proteolytic activ-
ity. The presence of the BACE1 inhibitor signiﬁcantly
reduced myelination when compared to the control condi-
tions (Fig. 5D–F) [ANOVA, F(2,13) = 7.421, P5 0.01].
These results indicated that interference with NRG1-ErbB
signalling reduced myelination in our co-culture system.
Neither the ErbB inhibitor [ANOVA, F(2,14) = 2.311,
P4 0.05] nor the BACE1 inhibitor [ANOVA,
F(2,13) = 1.452, P4 0.05] had a measurable effect on
axonal density (Fig. 5B–E). To assess whether the pharma-
cological blockade of NRG/ErbB signalling led to a reduc-
tion in Schwann cell proliferation, we quantiﬁed the
number of DAPI positive Schwann cell nuclei in our cul-
tures. Only the highest concentration of PD168393 resulted
Figure 2 Nodes of Ranvier and the basal lamina successfully form in co-cultures. (A) Clustering of voltage gated sodium channels at
the node, Caspr at the paranode and Kv1.2 at the juxtaparanode is detected after 4 weeks of myelination. (B) Sodium channels cluster between
the MBP positive internodes. (C) Abundant Caspr positive paranodes are detected after 6 weeks of myelination. (D) At the electron microscopy
level, the basal lamina can be observed (arrowheads) as well as individual myelin wraps. Not all the myelin wraps are tightly compacted at 6 weeks
(arrow), whereas after 14 weeks of myelination, the number of wraps has increased and are tightly compacted.
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in a reduction in Schwann cell numbers (Fig. 5G), consist-
ent with the fact that NRG1 promotes stem cell prolifer-
ation. When we assessed the protein levels of the full-length
and cleaved-terminal fragment of TIIINRG1 after neurons
have been treated with the BACE1 inhibitor, we found that
there was a reduction in the amount of cleaved-terminal
fragment, and an increase in the full-length levels with
both concentrations of BACE1 inhibitor. This corresponds
to the inhibition of the proteolytic cleavage of full-length
TIIINRG1, resulting in an accumulation of the full-length
and a reduction in the cleaved-terminal fragment. Similar
results were observed when assessing full-length and
cleaved fragment levels in the Bace1-/- mouse (Hu et al.,
2006; Willem et al., 2006).
Anti-disialosyl antibodies impair
myelination
Gangliosides containing disialosyl moieties are known to be
expressed by sensory neurons (Svennerholm et al., 1994).
Auto-antibodies directed against these gangliosides are
associated with acute (IgG) and chronic sensory/ataxic neu-
ropathies (IgM) with electrophysiological evidence of both
axonal degeneration and demyelination (Wicklein et al.,
1997; Miyazaki et al., 2001; Willison et al., 2001). We
therefore investigated the topographical targets and patho-
logical effects of anti-disialosyl antibodies using two mouse
IgG3 monoclonal antibodies (MOG12 and EG4) and the
human IgM monoclonal, HA1. After overnight incubation,
all antibodies had bound to exposed axolemma (at both the
nodes of Ranvier) (Figs 6A and 7A) and unmyelinated
axons (Figs 6A and 7B) within the mature co-cultures.
Nodal reactivity was sharply delimited by the paranodal
junction protein Caspr indicating that tight junctions at
the paranode are likely excluding access of these antibodies
to the internodal regions (Figs 6A and 7A). We did not
observe binding to Schwann cells. After overnight incuba-
tion with either mouse or human ADAs at 10 or 100 mg/ml,
the addition of normal human serum as a source of com-
plement produced axonal deterioration and myelin bleb-
bing within 2 h (Figs 6B and 7E). These changes were not
seen with antibody or normal human serum alone (Figs 6B,
and 7C and D). The prolonged addition of the low con-
centrations of mouse IgG anti-disialosyl antibodies (10 mg/
ml), without normal human serum, started at the onset of
myelination, signiﬁcantly reduced the proportion of myeli-
nation at 4 weeks (Fig. 6D and G) [n = 3, mean (95%
conﬁdence interval, CI) reduction versus control = 66%
(35% to 96%), P5 0.01, one-way ANOVA with Tukey
correction], without reducing the total axonal area itself
(Fig. 6D and F). Unlike the changes observed following
the addition of normal human serum, this condition did
not result in axonal degeneration. Likewise, there were no
morphological changes in the axons after 4 weeks, when
compared to control conditions without antibody (Fig. 6H
and I). Prolonged incubation with higher concentrations of
mouse IgG ADAs (50 mg/ml) almost entirely prevented mye-
lination [Fig. 6E and G, n = 3, mean (95% CI) reduction
versus control = 96% (64% to 127%), P5 0.001, one-way
ANOVA with Tukey correction], but also produced wide-
spread irregularities in the axonal neuroﬁlament-heavy
Figure 3 Myelination increases over time in culture.
Cultures were fixed and immunocytochemistry performed at (A) 2,
(B) 3, (C) 4, (D) 6 and (E) 14 weeks post-induction of myelination.
(A) The first MBP-positive internodes can be detected at 2 weeks.
Myelination was quantified (G) as a proportion of NF200-positive
staining (F). Levels of myelination steadily increase over time,
whereas axonal area remains unchanged from 4 weeks.
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staining (Fig. 6E and J). There was no signiﬁcant difference
between the two different mouse IgG anti-disialosyl antibo-
dies in terms of their observed effects on myelination at
either the high or low concentration (both P4 0.05, un-
paired t-test), and these results were pooled for the ﬁnal
analysis. No signiﬁcant effect on myelination was seen with
control antibodies (normal mouse IgG, Abcam) at either
high (50 mg/ml) or low (10 mg/ml) concentration
(P40.05, one-way ANOVA with Dunnett correction)
(Supplementary Fig. 4).
The prolonged addition of the human IgM monoclonal,
HA1, started at the onset of myelination, likewise resulted
in a dose-dependent reduction in axonal coverage by
myelin at 4 weeks [n = 3, mean (95% CI) reduction at
10 mg/ml versus control = 56% (35% to 77%), P5 0.001,
mean (95% CI) reduction at 50 mg/ml versus control = 75%
(54% to 96%), P5 0.0001, one-way ANOVA with Tukey
correction] (Fig. 7F–J). Neither antibody concentration
caused visible changes to axonal morphology (Fig. 7F–H)
or a signiﬁcant change in axonal area [one-way ANOVA
with Tukey correction, F(2,6) = 0.9833, P4 0.05] (Fig. 7I).
A human anti-disialosyl IgM antibody
induces demyelination
To establish whether ADAs could induce demyelination, in
addition to preventing myelination, established co-cultures
aged 9–12 months were used. With prolonged exposure to
HA1 at 50 mg/ml, numerous myelin internodes present at
baseline (revealed by live cell FluoroMyelinTM staining)
were absent on repeat images taken after 4 weeks (Fig.
8B). In comparison, under control conditions, the majority
of internodes remained stable over the same time period
(Fig 8A). Higher power images revealed no differences in
Figure 4 Overexpression of TIIINRG1 significantly increases myelination in the co-cultures. (A–D) Human iPSC-derived neurons
were transduced with an AAV containing a TIIINRG1 construct at a range of MOI’s. Cultures were fixed for immunocytochemistry or lysed for
protein extraction at 4 weeks post-induction of myelination. (E) Viral transduction had no effect on axonal outgrowth or morphology, with no
visible signs of neurite blebbing (insets in A–D). Scale bar = 50mm. (F) Myelination was similar in (A) untransduced and (B) 1  104 MOI
conditions, whereas a significant and dose dependent increase in myelination was observed in (C) 1  105 (P5 0.05) and (D) 1  106
(P5 0.001) conditions. (G) In the transduced neurons, western blot shows the increase in both the full-length (FL) (135 kDa) and cleaved-
terminal fragment (CTF) (60 kDa) of TIIINRG1 compared to untransduced control. The calnexin control demonstrates an even protein loading
across conditions.
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axonal morphology between the groups (Fig. 8C and D).
Furthermore, in HA1 treated cultures, presumed ongoing
demyelination could occasionally be observed, with
clumps of disintegrating myelin surrounding intact axons
(Fig. 8D). When quantiﬁed at 4 weeks, there was no sig-
niﬁcant difference in axonal area between HA1 treated and
control cultures [mean (95% CI) coverage difference for
HA1 versus control = 0.05 (1.24 to 1.13), P = 0.9039,
unpaired t-test] (Fig. 8E). However, the extent of myelin
loss (demyelination) was signiﬁcantly higher in the HA1
group [mean (95% CI) increased myelin loss with HA1
versus control = 10.54% (3.92 to 17.17), P = 0.0115, un-
paired t-test] (Fig. 8F).
Discussion
Our aim was to establish myelinating co-cultures from
iPSC-derived sensory neurons and use them to investigate
the physiology and pathology of axoglial interactions
within the peripheral nervous system. We found that, sur-
prisingly given the species difference, human iPSC-derived
sensory neurons can be reliably and efﬁciently myelinated
by rat Schwann cells. These co-cultures feature the expected
markers of a specialized axoglial relationship, including the
widespread formation of nodes of Ranvier. The cultures are
also extremely stable over time, which is a signiﬁcant
advantage compared to primary myelinating co-cultures,
and will enable axoglial physiology and disease pathogen-
esis to be investigated over long time periods.
iPSCs have become a fundamental tool for disease mod-
elling, drug and toxicology screening and regenerative
medicine. With the intrinsic capability of almost limitless
self-renewal, the theoretical capacity to differentiate into
essentially every cell type, and the potential to model a
pathogenic genotype by reprogramming cells from an af-
fected individual, iPSCs have attracted considerable atten-
tion (Soldner et al., 2012; Sterneckert et al., 2014;
Hockemeyer and Jaenisch, 2016). This led to rapid ad-
vances in the ﬁeld, both in terms of reprogramming meth-
ods and in the development of novel and improved
differentiation protocols for a large variety of cell types
(Mertens et al., 2016). The differentiation protocol for sen-
sory neurons used in the current study is exemplary
(Chambers et al., 2012). Using a combination of ﬁve
small molecular pathway inhibitors, this method produces
a sensory neuronal population within 2 weeks at an efﬁ-
ciency of 490%. Further characterization deﬁned these
neurons as molecularly and functionally comparable to
human sensory neurons derived from mature dorsal root
ganglia. The protocol was originally developed with the
aim of generating nociceptors, most (but not all) of which
have small diameter, unmyelinated axons. However, the
neurons generated are heterogenous (Young et al., 2014).
Figure 5 Pharmacological blockade of NRG1/ErbB signalling impairs myelination in the human/rat co-cultures. Irreversible
blockade of ErbB receptors with PD168393 at (B) 7 nM and (C) 70 nM dose-dependently reduces the formation of MBP positive internodes
compared to (A) control cultures. Inhibition of the b-secretase protease (BACE1) with (D) 50 nM and (E) 500 nM also results in a dose-dependent
reduction in the formation of myelin. The few remaining myelin internodes are indicated in B, D and E with arrowheads. (F) Quantification of the
myelin levels relative to an internal control. (G) Schwann cell numbers are reduced only with the highest concentration of PD168393. (H)
Treatment of iPSC-derived sensory neurons with BACE1 results in an accumulation in full-length (FL) TIIINRG1, and a reduction in the
cleaved-terminal fragment (CTF).
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We noted approximately a third of neurons generated using
this protocol had action potential characteristics of non-
nociceptive afferents (unpublished observation) and all
axons were immunoreactive for neuroﬁlament heavy
chain, a characteristic of large diameter axons. We there-
fore investigated whether these sensory axons could be
myelinated. We observed that iPSC-derived sensory neu-
rons were indeed able to engage in the highly complex
cell-to-cell interactions with Schwann cells, and successfully
undergo myelination. Direct comparisons of myelination
with primary co-cultures of rat DRG neurons with rat
Schwann cells have not been conducted however, qualita-
tively the onset and nature of myelination is very similar.
The longevity of our co-cultures is substantially greater
than primary rat/rat co-cultures, so whilst similar levels of
myelination may be initially observed after several weeks,
we observe a progressive increase in myelination over time.
Co-cultures could be maintained for 49 months without
Figure 6 Mouse IgG anti-disialosyl antibodies cause acute, complement dependent axonal degeneration while prolonged
application without a source of complement impairs myelination. (A) Both mouse IgG3 antibodies (mADAs, example shown is EG4,
blue) bind to unmyelinated axons and the nodal axolemma, but do not cross the paranodal junction (marked by Caspr, red). (B) With the
additional provision of normal human serum (NHS) as a source of complement, axonal degeneration can be observed after 2 h. (C–E and G)
Prolonged culture with mouse anti-disialosyl antibodies without a source of complement significantly reduces the extent of myelination at 4 weeks
at both low (10 mg/ml, P5 0.01) and high (40mg/ml EG4, 50mg/ml MOG12, P5 0.001) antibody concentrations. (F) Axonal area in antibody-
treated cultures is not reduced over this time period. Graphs show pooled data from three separate experiments using both anti-disialosyl
antibodies (EG4 and MOG12). Example images were treated with MOG12 (‘mADA’) or myelination medium only (‘Control’). (H–I) Axonal
morphology is no different from controls after 4 weeks of continuous incubation with low dose (10 mg/ml) mouse anti-disialosyl antibodies
without NHS, but (J) irregular axonal staining and blebbing is seen at 50mg/ml.
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loss of myelin or axonal integrity (Supplementary Fig. 2),
qualifying them for studies that require extremely long
timeframes.
The activation of the myelination process (Fig. 1) and the
formation of nodal structures (Fig. 2), require sequential
and highly complex reciprocal cellular interaction (Salzer,
2015). While many factors play a role in myelination,
including cAMP, brain-derived neurotrophic factor
(BDNF), Notch 1, cell adhesion molecules, and G-protein-
coupled receptors, NRG1-ErbB signalling has been estab-
lished as a key regulator of this process (Taveggia, 2016).
All NRG1 isoforms contain an epidermal growth factor
(EGF)-like signalling domain that can act on heterodimeric
ErbB2-ErbB3 receptors expressed at the Schwann cell mem-
brane; the membrane-bound type III isoform is thought to
be the most important signalling molecule for the regula-
tion of myelination in the PNS (Michailov et al., 2004;
Taveggia et al., 2005; Birchmeier and Bennett, 2016).
Using an AAV-mediated overexpression system or pharma-
cological inhibition, we ﬁnd that TIIINRG1 expressed on
human axons could strongly promote myelination. Levels
of NRG1 in the peripheral nervous system are regulated by
Figure 7 A CANOMAD associated human IgM anti-disialosyl antibody (HA1) also causes acute, complement dependent
axonal degeneration while prolonged application without a source of complement impairs myelination. (A) HA1 (green) binds to
nodal axolemma (flanked by Caspr, red) and to (B) unmyelinated axons (NF200, red), without any reactivity to Schwann cells (S100, blue). (C–E)
Short-term incubation with HA1 followed by normal human serum as a source of complement leads to (E) acute axonal degeneration. (F–H)
Prolonged incubation with HA1, without provision of complement, leads to a dose-dependent reduction in myelination over 4 weeks, quantified in
(J). No significant alteration to (F–H) axonal morphology or (I) axonal coverage was observed (P5 0.001 versus control).
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proteolytic cleavage by a range of secretase enzymes,
including BACE1 (Hu et al., 2006; Willem et al., 2006;
Fleck et al., 2016). The role of NRG1-ErbB signalling in
myelination of the rodent peripheral nervous system is well
established, and we have now shown that modulating
TIIINRG1 expression on human sensory axons also has a
key role in regulating myelination. Co-cultures also have
potential for drug and toxicology screening (Fig. 5). In
the last decade BACE1 has emerged as an important
target for experimental therapies in Alzheimer’s disease.
In addition to the proteolytic processing of NRG1,
BACE1 is one of the b-secretase enzymes required for the
endoproteolysis of the amyloid precursor protein (APP),
and hence the production of the 42-amino acid long b-
amyloid peptide (amyloid-b42), widely considered to be
neurotoxic and crucial during the early onset of
Alzheimer’s disease (Vassar, 2004). As a result, BACE1 in-
hibitors are currently in human clinical trials (Vassar et al.,
2014). Given the profound effect on the myelination of
human axons, the potential for BACE1 inhibition to pro-
duce deleterious effects on peripheral nerve function is
highlighted by this study. This may be a particular problem
for patients with pre-existing neuropathies (up to 8% of the
elderly population) (Martyn and Hughes, 1997), in which
ongoing repair may be critically important. NRG1 is now
also being considered as a target for clinical intervention.
Human based myelinating co-cultures should prove a useful
tool for screening the effects of drugs targeting this signal-
ling pathway.
iPSC-based assays also offer advantages in the investiga-
tion of autoimmune diseases. Indeed, non-myelinating cul-
tures of iPSC-derived motor neurons have recently been
used to study the immunopathology of multifocal motor
neuropathy associated anti-GM1 antibodies (Harschnitz
et al., 2016). Dysimmune processes underlying other
inﬂammatory neuropathies are known to target distinct
topographical regions of the peripheral nerve, including
the myelin sheath and specialized axonal domains formed
at the node of Ranvier and ﬂanking paranodal and juxta-
paranodal domains (Devaux et al., 2012; Querol et al.,
2013). These structures are not formed in pure neuronal
cultures, further highlighting the beneﬁts of myelinating co-
cultures. Currently, the speciﬁc antigen target in many in-
ﬂammatory neuropathies is elusive and the exact nature of
their pathology is uncertain. This is likely to be because
solid phase serological assays fail to recapitulate the com-
plex antigen environment created by cis interactions within
neural membranes, and the trans interactions, which char-
acterize axoglial connections and signalling. Such assays
provide little to no insight into pathological mechanisms.
The co-culture system thus has great promise for
strengthening clinical-serological correlations, identifying
new antigen targets, establishing pathological mechanisms,
and testing therapeutic strategies. A further advantage of
this culture system is its stability over time, facilitating the
more realistic study of longer term pathological processes.
Ganglioside antibodies have previously been shown to
cause acute axonal deterioration in the presence of comple-
ment (O’Hanlon et al., 2001; McGonigal et al., 2010),
which is again conﬁrmed by this study. We have now
shown that both mouse- and patient-derived anti-disialosyl
ganglioside antibodies disrupt myelination independently of
complement. The ﬁnding that these antibodies bind to the
axolemma and not directly to Schwann cells emphasizes the
importance of axon-derived signals in the formation and
maintenance of healthy myelin. These observations correl-
ate with the demyelinating electrophysiological pattern seen
in some acute sensory neuropathies associated with anti-
GD1b antibodies of the IgG class (Wicklein et al., 1997),
Figure 8 A CANOMAD associated human IgM anti-
disialosyl antibody induces complement independent
demyelination without evidence of axonal injury. (A and B)
Superimposed images of the same field of view of an established
myelinating co-culture 4 weeks apart. (A) Under control conditions
the pattern and extent of myelination at baseline (assessed by
FluoroMyelinTM staining, white) was largely maintained after 4
weeks further culture (assessed by MBP immunofluorescence, red).
(C) Myelin and axons were morphologically normal in these aged
co-cultures. (B) With prolonged exposure to HA1, numerous
internodes present at baseline were no longer apparent after 4
weeks (arrows). In some areas (arrowhead) fragmentation of myelin
could be seen. (D) At higher power in fixed tissue, myelin degen-
eration in such areas could be observed without loss of the
underlying axon. (E) When quantified, there was no significant dif-
ference in axon area between HA1 treated and control cultures, but
(F) the proportion of myelin loss was significantly greater with HA1
(P5 0.05).
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and with CANOMAD (associated with IgM anti-disialosyl
antibodies), which shows both axonal and demyelinating
features (Willison et al., 2001). These antibodies not only
induce demyelination, but also block de novo myelination
in this experimental system. Anti-ganglioside antibodies
have previously been shown to reduce axonal regeneration
in culture (Roze´s Salvador et al., 2016), and their persist-
ence in patients with GBS is associated with delayed recov-
ery (Bech et al., 1997). Our observations also suggest that
they may impair repair associated remyelination, with po-
tential implications for the optimal timing and duration of
immunomodulatory therapy in patients. The anti-disialosyl
antibodies in this study also react with GT1b, a known
ganglioside ligand for myelin associated glycoprotein
(MAG) providing one potential mechanism for altered axo-
glial interactions (Yang et al., 1996). MAG is involved in the
maintenance of myelin, whereas evidence of its role in the
initiation of peripheral nervous system myelination is con-
ﬂicting (Owens et al., 1990; Owens and Bunge, 1991;
Montag et al., 1994). Mice with disrupted ganglioside syn-
thesis do however display increased axonal degeneration and
demyelination within their peripheral nerves, possibly be-
cause the ganglioside-MAG interaction is absent (Sheikh
et al., 1999). Whether anti-disialosyl antibodies bound to
axonal gangliosides block this speciﬁc signal, affect another
unidentiﬁed pathway, or simply act as a non-speciﬁc phys-
ical barrier to axoglial interaction, remains to be determined.
In summary, we have developed a myelinating co-culture
system using human iPSC-derived sensory neurons and
rodent Schwann cells, which faithfully recapitulates the
axoglial signalling required for myelination. This co-culture
system can be used to screen drugs that may promote or
impede myelination and to investigate the immunopathol-
ogy of the inﬂammatory neuropathies.
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